National Guideline Clearinghouse | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for <em>IFNL3 (IL28B) genotype</em> and PEG interferon-α–based regimens.
Clinical Pharmacogenetics Implementation Consortium
Guideline Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α–based regimens.
Bibliographic Source(s)
Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR, Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141-6. [40 references] PubMed  |
Guideline Status
This is the current release of the guideline.
Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
Muir AJ1, Gong L2, Johnson SG3, Lee MT4, Williams MS5, Klein TE2, Caudle KE6, Nelson DR7; Clinical Pharmacogenetics Implementation Consortium (CPIC).
Abstract
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.
.png)
No hay comentarios:
Publicar un comentario